Current partner codePEPTIDESDE
NCT00036231·Phase 3·INTERVENTIONAL

Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction

Status

Terminated

Phase

Phase 3

Enrollment

Locations

0

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The purpose of the study is to determine the effect of multiple doses of secretin on autism.

Interventions

Treatment arms and agents.

DRUG

RG1068 (Synthetic Human Secretin)

Timeline

From registration to results.

  1. First posted

    May 9, 2002

  2. Study start

    Apr 2002

  3. Primary completion

    Not reported

  4. Study completion

    Not reported

  5. Results posted

    Not reported

  6. Registry updated

    Nov 21, 2005

Outcomes

What the study measures.

Primary outcomes

Not reported in the indexed record.

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
32 Months
Maximum age
59 Months
Sex
ALL
Healthy volunteers
No

* Autism * Gastrointestinal dysfunction

Study locations

0 registered sites.

No country data reported. Showing up to 24 locations stored in the fast local snapshot.

No study locations reported.

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Secretin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.